Scantox provides pre-clinical research services, including regulatory in-vivo toxicology studies, exploratory in-vivo work and disease model development, all services that are critical to any drug development process. In addition, the Company performs various histology and pathology services. Scantox plays a vital role in the Nordic pharma and biotech community, where the Company has established deep relationships and enjoys a broad and loyal customer base, leveraging its strong track-record and more than 40 years of scientific experience.
Scantox’s strategy is to further strengthen and expand its geographic footprint as well as its service offering, to successfully support drug development efforts for both local and global companies in the pharma, biotech, and medical device sectors. Impilo’s investment in Scantox is part of an overarching strategy to drive further consolidation within pre-clinical drug development and drug discovery in Europe to build a larger group and streamline the value chain with a broader offering across adjacent service areas.
